Trial Summary
What is the purpose of this trial?
This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
Eligibility Criteria
This trial is for people with a limited number of cancer spread sites (up to 5), who've had their primary tumor treated, and are not candidates for surgery. They should be in relatively good health otherwise, able to consent, and complete questionnaires in English. Pregnant women or those with certain medical conditions that make radiotherapy unsafe cannot join.Inclusion Criteria
I can take care of myself and am up and about more than half of the day.
My brain metastases have been approved for treatment by a specialized team.
I only need a PET-CT or PSMA-PET scan for certain conditions.
See 26 more
Exclusion Criteria
Pregnant or lactating women
I have signs of pressure on my spinal cord.
My first chemotherapy fully eliminated the cancer that can be measured.
See 7 more
Treatment Details
Interventions
- Stereotactic Ablative Body Radiotherapy (SABR) (Radiation Therapy)
Trial OverviewThe study tests Stereotactic Ablative Body Radiotherapy (SABR) on patients with few metastatic cancer sites. It aims to assess the side effects and potential survival benefits of this targeted high-dose radiation therapy compared to other treatments.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Stereotactic armExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
BC CancerPrince George, Canada
Loading ...
Who Is Running the Clinical Trial?
British Columbia Cancer AgencyLead Sponsor